Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: A retrospective claims database analysis

Ye, Xin; Sikirica, Vanja; Schein, Jeffrey; Grant, Richard W.; Zarotsky, Victoria; Doshi, Dilesh; Benson, Carmela; Riedel, Aylin Altan

doi:10.1016/j.clinthera.2008.01.023

Cited by 37 publications

(34 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(1) Furthermore, readmission to hospital is substantial with 20% readmitted to hospital for those who survive an episode of CAP and upwards of 10% of those treated as outpatients are subsequently admitted to hospital in the short term. (1)(2)(3)(4)(5)(6)(7) The in-hospital mortality is considerable (~10% in population based studies). (8) Among CAP outpatients, several small studies (<2000 patients) have estimated 30-day mortality rates from 0·1% to 2·5% (1,3,(9)(10)(11), although a recent administrative database study suggested 30-day mortality rates of at least 4% among elderly patients.…”

mentioning

confidence: 99%

Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort

Eurich

Marrie

Minhas-Sandhu

et al. 2015

Am J Respir Crit Care Med

103

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort

Eurich

Marrie

Minhas-Sandhu

et al. 2015

Am J Respir Crit Care Med

103

View full text Add to dashboard Cite

show abstract

“…One observational study by Ye et al [13] compared outcome and costs of treatment in outpatients with CAP after administration of levofloxacin (500 or 750 mg) versus macrolides: Although the rate of treatment failure was lower for the levofloxacin group, no differences were observed in term of costs, CAP-related hospitalisations and mortality.…”

Section: Outpatientsmentioning

confidence: 97%

“…No difference in mortality, clinical resolution or adverse effects; quinolones had higher eradication rate Ye et al [13] 2008 Observational Retrospective, enrolling 7526 patients…”

Section: Wardmentioning

confidence: 97%

What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy

Gattarello

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

Despite all published literature, controversies remain about the optimal antibiotic treatment in community-acquired pneumonia. The most debated issue is whether it is necessary to empirically start one or two antibiotics, i.e. whether or not to cover atypical agents. A review of the literature published from 2005 to present was completed, searching for new insights in antibiotic treatment in community-acquired pneumonia (CAP) focusing on monotherapy versus combined therapy. Forty-one articles were identified enrolling outpatients, and patients admitted to the ward and to the intensive care unit: 11 were meta-analyses, 8 clinical trials and 22 observational-prospective and retrospective-studies. Although controversies remain in the treatment of CAP, the use of combination therapy seems to be associated with a lower mortality in case of severe CAP that requires intensive care unit (ICU) admission, especially when a beta-lactam-macrolide association is delivered. Moreover, combination therapy is associated with better outcomes-although not always with a lower mortality-in cases of non-ICU patients with risk factors for a poor outcome, bacteraemic pneumococcal pneumonia and high suspicion of infection by atypical agents. In this setting, it appears that the best choice of treatment may be a beta-lactam-macrolide regimen.

show abstract

“…Показано, что частота клинических не удач при лечении левофлоксацином достоверно ниже, чем при назначении макролида (19,6 % vs 27 %; p = 0,049) при сравнимых экономических за тратах: фактическая стоимость лечения 1 пациента составила 427 ± 753 и 415 ± 2 193 долл. США соответ ственно (отношение шансов (95% ный доверитель ный интервал) для скорректированной стоимости -1,01 (0,54-1,87); p = 0,98) [131]. В сравнительном проспективном исследовании A.Anzueto et al внутри венной / пероральной терапии моксифлоксацином и левофлоксацином у пациентов с ВП старше 64 лет (n = 394; у 34 % -ХСН в анамнезе) показано, что ранняя клиническая эффективность после коротко го курса АБТ (3-5 суток) выше при применении моксифлоксацина, чем левофлоксацина (97,9 % vs 90 % соответственно; p = 0,01) при аналогичных Передовая статья исходах лечения, профиле безопасности и переноси мости обоих препаратов [132].…”

Section: антибактериальная терапияunclassified